Notably, the rs2108622 variant, which results in the CYP4F2 V433M substitution that abrogates CYP4F2 hydroxylation activity (Fig. 3, D and E), is associated with several cardiometabolic phenotypes, including diastolic blood pressure (beta 0.008, p-value=1.13 × 10–7), total cholesterol (beta 0.006, p-value=9.54 × 10–7), Non-HDL cholesterol (beta 0.008, p-value=4.71 × 10–6), and coronary artery disease (OR 1.02, p = 1.92 × 10–5) https://t2d.hugeamp.org/variant.html?variant=rs2108622. This evidence concerns the gene CYP4F2 and coronary artery disorder.